Otitis Media

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201    Business Wire Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201    Business Wire Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.

Reviewing Otonomy Inc. (OTIC)'s and Chimerix Inc. (NASDAQ:CMRX)'s results    The Hi New Ulm Otonomy Inc. (NASDAQ:OTIC) and Chimerix Inc. (NASDAQ:CMRX), are influenced by contrast since they are both players in the Biotechnology. These factors ...

(2018-2023) Otitis Media Market Drugs Dormant and Discontinued Pipeline Projects|analysis and forecast    Rochester Leader 2018 Otitis Media Market Report Renders an in-depth analysis of geographical regions and conditions, product/*service* types, applications, consumption, ...

Global Otitis Media Market by Disease Overview, Trends, Symptoms, Etiology, Diagnostic Methods, Insight, Epidemiology, Drug & Therapies Analysis and Industry Forecast 2019-2028    Bitcoin Journal The Global Otitis Media Market report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple ...

Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference    Odessa American IRVINE, Calif.--(BUSINESS WIRE)--Feb 20, 2019--Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing ...

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201    Business Wire Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.